Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2016

View Archived Issues

Enumeral and Pieris sign definitive license agreement

First clinical data reported for anti-CD47 monoclonal antibody Hu5F9-G4

Novartis initiates phase II trial of CLR-325 in chronic stable heart failure

Millendo Therapeutics begins phase II trial on ATR-101

Enanta Pharmaceuticals patents FXR agonists

European Commission approves Avastin plus Tarceva for advanced NSCLC with EGFR-activating mutations

Mochida Pharmaceutical discloses OX2 receptor antagonists

Oncothyreon changes name to Cascadian Therapeutics

Crispr Therapeutics and Anagenesis Biotechnologies enter collaboration for P2MC technology

Merck Patent presents IRAK inhibitors

Phase II trial of erenumab in chronic migraine prevention meets primary endpoint

Fibrocell Science reports negative results for phase II trial evaluating Azficel-T

Korea Institute of Science and Technology reports development of protein kinase inhibitors

Bayer Schering Pharma describes IRAK-4 inhibitors

FDA advisory committees recommend approval of Pfizer's ALO-02

Phase I results of BI-860585 for the treatment of solid tumors

Regorafenib administered to pediatric patients with solid tumors in phase I study

Update of clinical trials for cancer vaccine NY-ESO-1(c259) SPEAR T cells given at ASCO

FDA grants fast track designation to Remedy's Cirara

Theravance Biopharma and Takeda Pharmaceutical enter agreement for TD-8954

Galderma advances trifarotene program for lamellar ichthyosis

Ultragenyx and Takeda enter partnership to develop and commercialize rare genetic disease therapies

European Commission grants orphan drug designation to XLRP gene therapy candidate

PuriCore holds pre-IND meeting with FDA for PR-022 in atopic dermatitis

Activin-A inhibitor shows promise for the treatment of granulosa cell ovarian cancer

Aspen gains ex-U.S. commercialization rights to AstraZeneca's anesthetic portfolio

Phase III data for first expected trastuzumab biosimilar MYL-1401O

Capmatinib-gefitinib combination shows promise in EGFR-mutant/c-Met+ non-small cell lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...